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ScienceDirectThe neuroanatomical and neurochemical basis of
apathy and impulsivity in frontotemporal lobar
degeneration
L Passamonti1,2, CJ Lansdall1 and JB Rowe1,3,4Apathy and impulsivity are common and often coexistent
consequences of frontotemporal lobar degeneration (FTLD).
They increase patient morbidity and carer distress, but remain
under-estimated and poorly treated. Recent trans-diagnostic
approaches that span the spectrum of clinical presentations of
FTLD and parkinsonism, indicate that apathy and impulsivity
can be fractionated into multiple neuroanatomical and
pharmacological systems. These include ventral/dorsal
frontostriatal circuits for reward-sensitivity, response-
inhibition, and decision-making; moderated by noradrenaline,
dopamine, and serotonin. Improved assessment tools, formal
models of cognition and behavior, combinedwith brain imaging
and psychopharmacology, are creating new therapeutic
targets and establishing principles for stratification in future
clinical trials.Addresses
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Apathy and impulsivity are two problems that coexist
in frontotemporal lobar degeneration (FTLD) syn-
dromes, including the behavioral variant of frontotem-
poral dementia (bvFTD), primary progressive aphasia,
progressive supranuclear palsy (PSP), and corticobasal
syndrome [1,2,3,4]. Epidemiological data indicate that
apathy and impulsivity are common in FTLD syndromes
[5], and cause significant patient morbidity and carer
distress. Despite progress in understanding apathy and
impulsivity in other diseases [6], there is a limitedCurrent Opinion in Behavioral Sciences 2018, 22:14–20evidence base for clinical management in FTLD
syndromes.
Apathy and impulsivity have been conceived as belong-
ing to opposite ends of a behavioral spectrum of dopa-
mine-dependent abnormal motivation [7]. Although rel-
evant to some aspects of apathy and impulsivity in certain
neuropsychiatric disorders, this approach cannot explain
their frequent co-occurrence in FTLD, or the fact that
FTLD patients with more apathy also manifest more
impulsivity (Figure 1) [8]. As a concrete illustration of
their co-existence, we commonly observe apathetic
patients (e.g. sitting in a chair for hours) whose first action
in the day is an uncontrolled and impulsive movement
that put them at risk of falling and reporting injuries. This
‘alliance’ of apathy and impulsivity is also acknowledged
in the clinical diagnostic criteria for bvFTD [4] and
PSP [3].
We propose that apathy and impulsivity are behavioral
constructs with multiple components, and that these
components are positively correlated due to common-
alities in neuroanatomical and pharmacological conse-
quences of pathology, leading to dysregulation of deci-
sion-making, response-inhibition, and motivation.
Alternatively, apathy and impulsivity may originate
from separate brain structures and pharmacological
mechanisms which are difficult to fractionate empirically
due to the widespread nature of the FTLD-related
pathological changes. However, the co-existence of apa-
thy and impulsivity in other, non-degenerative, condi-
tions (e.g. drug addiction) suggests that this latter hypoth-
esis is less likely [9,10].
In parallel with correlative investigations of the neuroan-
atomical substrates of apathy and impulsivity, we present
a computational approach embedded in the decision
theory to describe and characterize the co-existence of
apathy and impulsivity in FTLD syndromes in terms of
latent neurocognitive mechanisms [11,12].
Finally, we highlight the role played by neurotransmitters
other than dopamine, in part because apathy and impul-
sivity in FTLD are clinically unresponsive to standard
dopaminergic therapies and in part because of emerging
evidence of serotonergic and noradrenergic contributions
to both apathy and impulsivity [13–16].www.sciencedirect.com
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Correlation between the self-rated Apathy Evaluation Scale (minimum
score 18) and Barratt Impulsiveness Scale (minimum score 30) in
73 patients with frontotemporal lobar degeneration syndromes (PSP
25, CBS 17, PPA 17, bvFTD 14; Pearson’s Correlation r = 0.495,
P < 0.001). PSP, progressive supranuclear palsy; CBS, corticobasal
syndrome; PPA, primary progressive aphasia; bvFTD, behavioral
variant of frontotemporal dementia.
Figure 2
a = ‘Go’ boundary
0 = ‘No-Go’ boundary
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(a) Examples of trajectories of the ‘drift-diffusion’ model. The two
boundaries (a & 0) represent the Go and No-Go decisions. The drift-
rate (velocity) represents the rate of accumulation of evidence. The
diffusion process begins at a starting point between the two
boundaries (z*a) until the accumulated evidence reaches one of the
two boundaries. The predicted movement latency is the sum of the
duration of the diffusion process and the non-decision time (Ter). (b)
Progressive supranuclear palsy (PSP) leads to exaggerated response
bias toward the Go decision boundary, reduced non-decision time
(Ter) and slow accumulation rate. This combination renders PSP
patients both impulsive and slow, in a parsimonious and biologically
plausible decision-model. The pictures in panel (a) and (b) have been
adapted from Ref. [17]. PD, Parkinson’s disease.Neurocognitive mechanisms of apathy and
impulsivity
The examination of behavioral profiles (latencies, accu-
racy, choice preferences) in terms of an accumulation-to-
threshold decision model [17]; or effort allocation models
[18] are key examples of model-based approaches to
study apathy and impulsivity. Such models can parame-
terize effort, fatigue, reward expectations and behavioral
biases, and other latent variables related to apathy and
impulsivity [19,20,21,22]. Differences in the accumula-
tion of ‘evidence’ for effort, or the variation in decision
thresholds according to reward, can be mapped to differ-
ences in brain structure and function [23].
This powerful modeling approach is beginning to eluci-
date the etiology of behavioral changes in FTLD and
Parkinsonian syndromes, such as the similarly deleterious
effect of PSP and Parkinson’s disease (PD) on response
inhibition (Figure 2a). A ‘drift-diffusion’ model describes
the binary-choice between action and inhibition in a Go/
No-Go paradigm, with neuronal ‘accumulators’ integrat-
ing the momentary evidence over-time [20,21,22]. When
this evidence reaches a threshold, the agent is committed
to response, or inhibition of a response. Despite their
profound akinesia, PSP patients, relative to PD patients
and controls, have a markedly increased bias toward
making a Go response. However, they are severely
impaired at accumulating the necessary additional evi-
dence to commit to a response [17]. Through the compu-
tational model of patient behavior, one can see how PSP
patients are simultaneously prone to impulsivity (i.e. biaswww.sciencedirect.comtoward a responding, plus noise) and apathy (severe
difficulty to reach threshold) (Figure 2b) [17]. In contrast
to model parameters, the mean reaction-times and errors
did not reveal the cognitive deficits that distinguished
PSP patients from PD patients and controls [17]. Latent
cognitive variables for effort and reward are similarly
derived from saccadic responses [24], and although only
applied thus far to PD, this approach has potential
advantages to study FTLD, where akinesia or rigidity
may interfere with responding over and above the cogni-
tive disorders underlying apathy and impulsivity.
Apathy
The composite nature of goal-directed behavior sup-
ported the theoretical decomposition of apathy into emo-
tional/motivational, cognitive, and behavioral (‘auto-
activation’) subtypes. The first variant relates to blunted
affect, while the cognitive apathy closely resembles the
typical executive deficits observed in FTLD syndromes.Current Opinion in Behavioral Sciences 2018, 22:14–20
16 Apathy and motivation
Figure 3
White-Matter Changes – Patient Ratings
Grey-Matter Changes – Carer Ratings
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Voxel-based-morphometry analyses revealed distinct white-matter or
grey-matter correlates for patient-related, carer-related and task-
related principal components (after [8]). Patient self-ratings correlated
with white-matter atrophy in cortico-spinal circuits while carer ratings
correlated with diffuse grey-matter deficits in frontostriatal and
frontotemporal regions. Response-inhibition impairments on behavioral
paradigms assessing impulsivity (i.e. stop signal task) correlated with
focal cortical atrophy in prefrontal cortex regions involved in cognitive
control. The color bar represents t-statistics.However, the relationship between apathy and cognition
remains unclear; apathy has been linked to rapid cogni-
tive/functional decline [25], while others have reported
no correlation between apathy and cognition [26]. The
‘auto-activation’ variant reflects a reduced ability to self-
generate motor patterns without external prompting.
This distinction is clinically heuristic but a clear oper-
ationalization of such subtypes is needed to link clinical
observations to modern cognitive neuroscience ontolo-
gies and their neuroanatomical substrates.
Although direct evidence linking brain structural deficits
to different modalities of apathy in FTLD syndromes
remains limited, the motivational apathy has been
hypothesized to arise from deficits from orbital/ventro-
medial prefrontal cortex (PFC)/ventral striatum circuits;
the cognitive apathy from dorsolateral-PFC/caudate net-
works; and the ‘auto-activation’ apathy from premotor/
motor circuits including the supplementary motor area
(SMA) and pre-SMA [27]. Dysfunction of the latter circuit
in FTLD syndromes can cause the failure to self-gener-
ate motor patterns, over and above blunted affect or
cognitive dysfunction, in keeping with evidence for this
circuit in voluntary action selection in health [20,28] and
poor signal-to-noise in motor plans arising from the
medial frontal cortex [29]. This ‘auto-activation’ deficit
can also be formulated as a failure to reach a necessary
activation threshold, by leakage, decay or refractoriness in
the frontoparietal neuronal ensembles that represent
actions [17].
Nevertheless, there is lack of consistency across studies
examining the neuroanatomical substrate of apathy in
FTLD, due to limited numbers of patients, lenient
statistical thresholds, and the inclusion of single diagnos-
tic entities which reduces the generalization of previous
studies. To overcome these limitations, we recommend
multiple modes of assessment of apathy (e.g. behavioral
tests, questionnaires from multiple sources, wearables
technologies) as well as trans-diagnostic approaches that
emphasize the commonality of the manifestation of apa-
thy across the broad clinical spectrum of FTLD diagno-
ses. This enables a data-driven approach to interrogate
the phenomenology and etiology of apathy and impulsiv-
ity [8,30]. For example, Lansdall et al. used a principal
components analysis of multiple questionnaires and lab-
oratory tests, combined with structural magnetic reso-
nance imaging [8,30]. They found a positive correlation
between measures of apathy and impulsivity (Figure 3)
and a dissociation between patient ratings, carer ratings,
and dissociable neural correlates of the different modes of
apathy and impulsivity, depending on the rater (Figure 3)
[8]. Carers’ observations of apathetic changes in behavior
correlated with diffuse atrophy in frontostriatal and fron-
totemporal regions, while patients’ reports related to
deficits in motor networks, suggesting that patients retain
insight in some aspects of their disability. These findingsCurrent Opinion in Behavioral Sciences 2018, 22:14–20imply that the aspects of FTLDwhich distress carers and
patients differ: future studies targeting patient-reported
or carer-reported symptoms should choose outcome mea-
sures accordingly.
Impulsivity
Impulsivity is a multi-faceted construct, which reflects
the tendency to act prematurely, with adverse conse-
quences, or with insufficient evidence to make a decision
[31]. Such definitions imply the distinction of impulsivity
into separate neurocognitive systems, with identifiable
neuroanatomical and neurochemical components. For
example, aberrant processing of reward-expectation and
delay-discounting measures (‘risky decision-making’ and
‘waiting impulsivity’), differ from response-inhibition
deficits and cognitive dysregulation (‘stopping’ and
‘reflection’ impulsivity) [31].www.sciencedirect.com
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Left panel. At the macroscopic examination, a patient with
progressive supranuclear palsy (PSP) shows, relative to a healthy
control, paler locus coeruleus (red arrows) reflecting reduced
intracellular neuromelanin. Right panel. There is also evidence that
tau pathology (red arrows) is present in the locus coeruleus in PSP.The neural determinants of impulsivity in FTLD syn-
dromes include: subcortical FTLD-related pathological
changes within striatal, thalamic, and sub-thalamic neu-
rons which affect reward processing and dis-inhibition of
thalamo-cortical loops, with consequent biases toward
contextually inappropriate actions [21,22,32]; and neo-
cortical pathology, especially in PFC networks, which
impair decision-making and action selection processes
[33]. Lesions at different points across the functional
gradients of interlocking PFC-striato-thalamo-cortical cir-
cuits affect different modes of impulsivity [31].
For example, degeneration of ‘limbic’ ventral PFC-striatal
circuits leads to risky decision-making and delay intoler-
ance while neurodegeneration in dorsal ‘motor’ and
‘cognitive’ circuits impairs the ability to refrain from or
cancel inappropriate actions. These effects span animal
models of impulsive disorders [34], neuroimaging data from
individuals with impulsive neurodevelopmental disorders
[35] and adult neuropsychiatric patients (e.g. obsessive-
compulsive disorders and PD) [21,22,36]. The prevalence
of impulsivity in these diverse conditions highlights the
value of translational and trans-diagnostic approaches to
elucidate the neural underpinnings of impulsivity [8,30].
In the study by Lansdall et al. [12], the response-inhibition
deficits observed during laboratory-based behavioral para-
digms (e.g. the stop-signal task of response cancelation)
correlated with focal atrophy in the inferior frontal gyrus
and pre-SMA. These are two critical ‘hubs’ in cognitive and
motor control, and the target of therapeutic strategies which
we consider in the next section [7,13–15].
Neuropharmacology of apathy and impulsivity
The emotional/motivational contributors to apathy have
been linked to the dopaminergic reward system [37], but
the pharmacology of ‘auto-activation’ deficits is unclear. A
link between dopamine, reward, and motivation is well
established in health and PD [38], but the motor and
affective components of incentive motivation are disso-
ciated and the principal determinants of apathy in PD
may be distinct from apathy in FTLD [39]. In clinical
practice, apathy in FTLD syndromes is frequently unre-
sponsive to anti-parkinsonian dopaminergic medications,
although dopamine deficiency is common in FTLD, not
only the overtly parkinsonian disorders like PSP, but also
the bvFTD. For example, half cases of FTD-linked
C9orf72 mutation develop parkinsonism, and this common
mutation is associated with striatal dopamine deficiency.
The extent to which this causes apathy and impulsivity, as
opposed to atrophy on frontostriatal circuits, remains
unclear. It is possible that dopamine deficiency in some
circuits and the relative preservation in other circuits is
accompanied by dopaminergic ‘overdose’, as in PD [40],
contributing to impulsivity in FTLD syndromes.
We propose that dysfunction of the noradrenergic system
may play a key role in the pathogenesis of apathy,www.sciencedirect.comespecially in FTLD syndromes [16]. There are early
pathological changes in the locus coeruleus (LC) in post
mortem tissue from FTLD patients (Figure 4) [33]. The
LC is the principal source of noradrenaline in the fore-
brain, which regulates the neuronal signal-to-noise ratio
in the neocortex, gating information processing and mod-
ulating arousal [41]. It is possible that the dopaminergic
and noradrenergic systems influence different compo-
nents of goal-directed behavior (e.g. motivation and
energization) [41,42], but such a dichotomy is over-
simplistic, and there is counter evidence for strong inter-
actions between the dopaminergic and noradrenergic
neurotransmission [42].
Impulsivity in FTLD syndromes may reflect dysfunc-
tions in multiple monoaminergic systems, including sero-
tonin, noradrenaline, and dopamine [43]. The reduction
of serotonin in FTLD reported by Bowen and Proctor
through post mortem studies, led Hughes and colleagues
to test whether the serotonin reuptake inhibitor citalo-
pram could restore the functional systems for response
inhibition [44]. As predicted, bvFTD patients had a
functional deficit in the PFC when required to inhibit
actions, but this deficit was restored by citalopram. Clini-
cal trials are necessary before this approach could be
introduced therapeutically, but the study indicates the
value of a translational approach, across species and across
disorders [13,44].
Noradrenaline is necessary to effectively cancel ongoing
behaviors when the context changes, in animal models
and healthy humans [45]. There is growing evidence for
the role of noradrenaline deficiency in impulsivity in
FTLD syndromes [14,15,46]. The early and severe
pathology in the LC in FTLD [33,47] suggests that
restoring noradrenergic neurotransmission might be aCurrent Opinion in Behavioral Sciences 2018, 22:14–20
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Shared neuroanatomical and neurochemical mechanisms underlying apathy and impulsivity in frontotemporal lobar degeneration syndromes. (a)
Different modes of apathy and impulsivity are mediated by relatively segregated frontostriatal circuits (the frontal and striatal areas sharing the
same coloring show direct anatomical and functional connectivity) [48,49]. (b) The dopaminergic, noradrenergic, and serotoninergic systems are
involved in regulating different aspects of apathy and impulsivity. Abbreviations: dACC, dorsal anterior cingulate cortex; sgACC, subgenual anterior
cingulate cortex; vmPFC, ventromedial prefrontal cortex; mOFC, medial orbitofrontal cortex; VS, ventral striatum; SMA, supplementary motor area;
dmPFC, dorsomedial prefrontal cortex; aPFC, anterior prefrontal cortex; Put, putamen; DLPFC, dorsolateral prefrontal cortex; VLPFC, ventrolateral
prefrontal cortex; lOFC, lateral orbitofrontal cortex; Caud, caudate; VTA, ventral tegmental area; SN, substantia nigra; LC, locus coeruleus; RN,
raphe nuclei. The pictures in panel (a) have been adapted from Ref. [50].therapeutic target for impulsivity. One candidate is the
noradrenergic reuptake inhibitor atomoxetine, which
restores activity and connectivity in inhibitory control
networks in another disorder with noradrenergic defi-
ciency, PD [14]. Together, these results suggest that
targeting noradrenergic transmission may be a useful
treatment for apathy and impulsivity in FTLD
syndromes.
Concluding remarks
We propose that apathy and impulsivity are not opponent
manifestations of a unidimensional behavioral spectrum,
but instead are multi-dimensional behavioral constructs
resulting from common neuroanatomical and neurochem-
ical deficits (Figure 5). To improve effective therapeutic
strategies in FTLD, we recommend targeting apathy and
impulsivity jointly, ensuring that chosen assessment tools
capture each of their principal dimensions. There is a
pressing need to develop improved assessment tools for
apathy and impulsivity, to empower clinical trials in terms
of stratification and outcome markers. These areCurrent Opinion in Behavioral Sciences 2018, 22:14–20especially relevant to trans-diagnostic therapies, which
would maximize the impact of effective new treatments
to a larger population of patients and carers alike.
Conflict of interest statement
Nothing declared.
Funding
This work was funded by the Wellcome Trust (103838),
the Medical Research Council (MC-A060-5PQ30; and
MR/P01271X/1) and the James S McDonnell Foundation
(Understanding human cognition, scholar award).
References and recommended reading
Papers of particular interest, published within the period of review,
have been highlighted as:
 of special interest
1. Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR,
Rowe JB: Validation of the new consensus criteria for the
diagnosis of corticobasal degeneration. J Neurol Neurosurg
Psychiatry 2014, 85:925-929.www.sciencedirect.com
Apathy and impulsivity in frontotemporal lobar degeneration Passamonti, Lansdall and Rowe 192. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M,
Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF et al.:




Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA,
Lang AE, Mollenhauer B, Muller U, Nilsson C, Whitwell JL et al.:
Clinical diagnosis of progressive supranuclear palsy: the
movement disorder society criteria. Mov Disord 2017, 32:853-
864.
This landmark paper revises the diagnostic criteria for progressive supra-
nuclear palsy and eight sub-types based on clinical features. Of particular
relevance to this review is the ‘PSP-F’ variant with early frontal cognitive/
behavioral signs, including apathy and impulsivity. Cognitive/behavioral
changes are widely reported in PSP, but may often be masked by or
followed by motor features, and these new criteria provide a critical step
toward formal recognition of non-motor consequences of PSP.
4. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH,
Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU
et al.: Sensitivity of revised diagnostic criteria for the
behavioural variant of frontotemporal dementia. Brain 2011,
134:2456-2477.
5. Coyle-Gilchrist IT, Dick KM, Patterson K, Vazquez Rodriquez P,
Wehmann E, Wilcox A, Lansdall CJ, Dawson KE, Wiggins J,
Mead S et al.: Prevalence, characteristics, and survival of
frontotemporal lobar degeneration syndromes. Neurology
2016, 86:1736-1743.
6. Ersche KD, Jones PS, Williams GB, Turton AJ, Robbins TW,
Bullmore ET: Abnormal brain structure implicated in stimulant
drug addiction. Science 2012, 335:601-604.
7. Sinha N, Manohar S, Husain M: Impulsivity and apathy in
Parkinson’s disease. J Neuropsychol 2013, 7:255-283.
8.

Lansdall CJ, Coyle-Gilchrist ITS, Jones PS, Vazquez Rodriguez P,
Wilcox A, Wehmann E, Dick KM, Robbins TW, Rowe JB: Apathy
and impulsivity in frontotemporal lobar degeneration
syndromes. Brain 2017, 140:1792-1807.
This paper reports the structural brain changes associated with different
types of apathy and impulsivity, across the spectrum of disorders caused
by frontotemporal lobar degeneration (frontotemporal dementia, progres-
sive supranuclear palsy, and corticobasal syndrome). The positive cor-
relation between apathy and impulsivity (as observed by carers) indicates
the need for a unified therapeutic strategy. The lack of correlation
between patient and carer ratings, and objective behavioral measures,
highlights the need of better assessment tools and revised outcome
measures for clinical trials.
9. Cattie JE, Woods SP, Iudicello JE, Posada C, Grant I, Group T:
Elevated neurobehavioral symptoms are associated with
everyday functioning problems in chronic methamphetamine
users. J Neuropsychiatry Clin Neurosci 2012, 24:331-339.
10. Winhusen TM, Somoza EC, Lewis DF, Kropp FB, Horigian VE,
Adinoff B: Frontal systems deficits in stimulant-dependent
patients: evidence of pre-illness dysfunction and relationship
to treatment response. Drug Alcohol Depend 2013, 127:94-100.
11. PessiglioneM, Vinckier F, Bouret S, Daunizeau J, Le Bouc R:Why
not try harder? Computational approach to motivation
deficits in neuro-psychiatric diseases. Brain 2017. Epub ahead
of print.
12. Teufel C, Fletcher PC: The promises and pitfalls of applying
computational models to neurological and psychiatric
disorders. Brain 2016, 139:2600-2608.
13. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T,
Huddleston C, Rae CL, Regenthal R, Sahakian BJ et al.: Selective
serotonin reuptake inhibitionmodulates response inhibition in
Parkinson’s disease. Brain 2014, 137:1145-1155.
14. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T,
Huddleston C, RaeCL, Regenthal R, Sahakian BJ et al.: Improving
response inhibition in Parkinson’s disease with atomoxetine.
Biol Psychiatry 2015, 77:740-748.
15. Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS,
Rodriguez PV, Coyle-Gilchrist I, Regenthal R, Altena E et al.:
Predicting beneficial effects of atomoxetine and citalopramon
response inhibition in Parkinson’s disease with clinical and
neuroimaging measures. Hum Brain Mapp 2016, 37:1026-1037.www.sciencedirect.com16. Loued-Khenissi L, Preuschoff K: Apathy and noradrenaline:
silent partners to mild cognitive impairment in Parkinson’s
disease? Curr Opin Neurol 2015, 28:344-350.
17. Zhang J, Rittman T, Nombela C, Fois A, Coyle-Gilchrist I,
Barker RA, Hughes LE, Rowe JB: Different decision deficits
impair response inhibition in progressive supranuclear palsy
and Parkinson’s disease. Brain 2016, 139:161-173.
18. Le Bouc R, Rigoux L, Schmidt L, Degos B, Welter ML, Vidailhet M,
Daunizeau J, Pessiglione M: Computational dissection of
dopamine motor and motivational functions in humans. J
Neurosci 2016, 36:6623-6633.
19. Forstmann BU, Ratcliff R,Wagenmakers EJ:Sequential sampling
models in cognitive neuroscience: advantages, applications,
and extensions. Annu Rev Psychol 2016, 67:641-666.
20. Zhang J, Rowe JB: Dissociable mechanisms of speed-accuracy
tradeoff during visual perceptual learning are revealed by a
hierarchical drift-diffusion model. Front Neurosci 2014, 8:69.
21.

Cavanagh JF, Wiecki TV, Cohen MX, Figueroa CM, Samanta J,
Sherman SJ, Frank MJ: Subthalamic nucleus stimulation
reverses mediofrontal influence over decision threshold. Nat
Neurosci 2011, 14:1462-1467.
The effect of subthalamic nucleus (‘deep brain’) stimulation on the cortical
electrophysiological basis of decision-making epitomizes the use of
diffusion-drift computational models to examine clinical disorders and
their treatment. The degree of medial prefrontal cortex activity positively
correlated with the decision boundary threshold. Deep brain stimulation
of the subthalamic nucleus reduced the threshold and made patient
choices more impulsive.
22. Pote I, Torkamani M, Kefalopoulou ZM, Zrinzo L, Limousin-
Dowsey P, Foltynie T, Speekenbrink M, Jahanshahi M:
Subthalamic nucleus deep brain stimulation induces
impulsive action when patients with Parkinson’s disease act
under speed pressure. Exp Brain Res 2016, 234:1837-1848.
23. Meyniel F, Goodwin GM, Deakin JW, Klinge C, MacFadyen C,
Milligan H, Mullings E, Pessiglione M, Gaillard R: A specific role
for serotonin in overcoming effort cost. Elife 2016, 5.
24.

Manohar SG, Chong TT, Apps MA, Batla A, Stamelou M,
Jarman PR, Bhatia KP, Husain M: Reward pays the cost of noise
reduction in motor and cognitive control. Curr Biol 2015,
25:1707-1716.
A novel saccadic distraction task was developed to quantify the impact of
Parkinson’s disease on the speed and accuracy of the eye movements
under varying levels of reward. Critically, a computational model was
used to test the hypothesis that dopamine deficits alter reward sensitivity
in Parkinson’s disease. Specifically, the model revealed the cost of
producing precise responses, balancing effort and reward. This model
provides a mechanistic and quantifiable approach to study apathy and its
treatment.
25. van Dalen JW, Van Wanrooij LL, Moll van Charante EP, Richard E,
van Gool WA: Apathy is associated with incident dementia in
community-dwelling older people.Neurology 2018, 90:e82-e89.
26. Pirogovsky-Turk E, Moore RC, Filoteo JV, Litvan I, Song DD,
Lessig SL, Schiehser DM: Neuropsychiatric predictors of
cognitive decline in parkinson disease: a longitudinal study.
Am J Geriatr Psychiatry 2017, 25:279-289.
27. Ducharme S, Price BH, Dickerson BC: Apathy: a neurocircuitry
model based on frontotemporal dementia. J Neurol Neurosurg
Psychiatry 2017. Epub ahead of print.
28. Rae CL, Nombela C, Rodriguez PV, Ye Z, Hughes LE, Jones PS,
Ham T, Rittman T, Coyle-Gilchrist I, Regenthal R et al.:
Atomoxetine restores the response inhibition network in
Parkinson’s disease. Brain 2016, 139:2235-2248.
29. Wolpe N, Wolpert DM, Rowe JB: Seeing what you want to see:
priors for one’s own actions represent exaggerated
expectations of success. Front Behav Neurosci 2014, 8:232.
30. Lansdall CJ, Coyle-Gilchrist ITS, Jones PS, Va´zquez Rodrı´guez P,
Wilcox A, Wehmann E, Dick KM, Robbins TW, Rowe JB: White
matter change with apathy and impulsivity in frontotemporal
lobar degeneration syndromes. Neurology 2017. (in press).
31. Dalley JW, Robbins TW: Fractionating impulsivity:
neuropsychiatric implications.Nat Rev Neurosci 2017, 18:158-171.Current Opinion in Behavioral Sciences 2018, 22:14–20
20 Apathy and motivation32. Passamonti L, Vazquez Rodriguez P, Hong YT, Allinson KS,
Williamson D, Borchert RJ, Sami S, Cope TE, Bevan-Jones WR,
Jones PS et al.: 18F-AV-1451 positron emission tomography in




Irwin DJ, Brettschneider J, McMillan CT, Cooper F, Olm C,
Arnold SE, Van Deerlin VM, Seeley WW, Miller BL, Lee EB et al.:
Deep clinical and neuropathological phenotyping of Pick
disease. Ann Neurol 2016, 79:272-287.
This detailed neuropathological examination of patients with Pick’s dis-
ease revealed the spatiotemporial evolution of pathological tau deposi-
tion: originating in limbic/paralimbic cortex (Phase I), followed by sub-
cortical structures, including basal ganglia, locus coeruleus and raphe
nuclei (Phase II), then the primary motor cortex and pre-cerebellar nuclei
(Phase III) and finally the visual cortex (Phase IV). These sequential phases
are shown to reflect the evolution of clinical symptoms, degeneration on
imaging metrics and disease duration.
34. Robbins TW, Gillan CM, Smith DG, de Wit S, Ersche KD:
Neurocognitive endophenotypes of impulsivity and
compulsivity: towards dimensional psychiatry. Trends Cogn
Sci 2012, 16:81-91.
35. Arnsten AF, Rubia K: Neurobiological circuits regulating
attention, cognitive control, motivation, and emotion:
disruptions in neurodevelopmental psychiatric disorders. J
Am Acad Child Adolesc Psychiatry 2012, 51:356-367.
36. Jahanshahi M, Obeso I, Rothwell JC, Obeso JA: A fronto-striato-
subthalamic-pallidal network for goal-directed and habitual
inhibition. Nat Rev Neurosci 2015, 16:719-732.
37. Chong TT, Husain M: The role of dopamine in the
pathophysiology and treatment of apathy. Prog Brain Res 2016,
229:389-426.
38. Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH,
Fallon S, Barker RA, Owen AM: Parkinson’s disease and
dopaminergic therapy — differential effects on movement,
reward and cognition. Brain 2008, 131:2094-2105.
39. Schmidt L, d’Arc BF, Lafargue G, Galanaud D, Czernecki V,
Grabli D, Schupbach M, Hartmann A, Levy R, Dubois B et al.:
Disconnecting force from money: effects of basal ganglia
damage on incentive motivation. Brain 2008, 131:1303-1310.
40. Robbins TW, Cools R:Cognitive deficits in Parkinson’s disease:
a cognitive neuroscience perspective. Mov Disord 2014,
29:597-607.
41. Aston-Jones G, Waterhouse B: Locus coeruleus: from global
projection system to adaptive regulation of behavior.Brain Res
2016, 1645:75-78.Current Opinion in Behavioral Sciences 2018, 22:14–2042.

Varazzani C, San-Galli A, Gilardeau S, Bouret S: Noradrenaline
and dopamine neurons in the reward/effort trade-off: a direct
electrophysiological comparison in behaving monkeys.
J Neurosci 2015, 35:7866-7877.
Neurophysiological recording in monkeys demonstrated that the firing of
dopaminergic neurons in the substantia nigra encode the reward-value
associated with decision-making. Conversely, the firing of noradrenergic
neurons in the locus coeruleus was implicated in ‘energizing’ behavior so
as to face the challenges associated with a particular task, especially in
terms of the effort required to produce an action.
43. Murley A, Rowe JB: Neurotransmitter deficits from




Hughes LE, Rittman T, Regenthal R, Robbins TW, Rowe JB:
Improving response inhibition systems in frontotemporal
dementia with citalopram. Brain 2015, 138:1961-1975.
This double-blind placebo-controlled pharmaco-magnetoencephalogra-
phy study demonstrated the impact of serotonergic augmentation on
response-inhibition systems in patients with frontotemporal dementia.
The NoGo-N2 and NoGo-P3 components in the frontal and temporal
lobes were significantly decreased in patients, relative to controls, but
restored by drug treatment even in the presence of irreversible focal
atrophy.
45. Dela Pena I, Dela Pena IJ, de la Pena JB, KimHJ, Shin CY, Han DH,
Kim BN, Ryu JH, Cheong JH: Methylphenidate and
atomoxetine-responsive prefrontal cortical genetic overlaps
in “impulsive” SHR/NCrl and Wistar rats. Behav Genet 2017.
Epub ahead of print.
46. Borchert RJ, Rittman T, Passamonti L, Ye Z, Sami S, Jones SP,
Nombela C, Vazquez Rodriguez P, Vatansever D, Rae CL et al.:
Atomoxetine enhances connectivity of prefrontal networks in
Parkinson’s disease.Neuropsychopharmacology 2016, 41:2171-
2177.
47. Haglund M, Friberg N, Danielsson EJ, Norrman J, Englund E: A
methodological study of locus coeruleus degeneration in
dementing disorders. Clin Neuropathol 2016, 35:287-294.
48. Voon V, Dalley JW: Translatable and back-translatable
measurement of impulsivity and compulsivity: convergent and
divergent processes. Curr Top Behav Neurosci 2016, 28:53-91.
49. Haber SN: Corticostriatal circuitry. Dialogues Clin Neurosci
2016, 18:7-21.
50. Morris LS, Kundu P, Dowell N, Mechelmans DJ, Favre P, IrvineMA,
Robbins TW, Daw N, Bullmore ET, Harrison NA et al.: Fronto-
striatal organization: defining functional and microstructural
substrates of behavioural flexibility. Cortex 2016, 74:118-133.www.sciencedirect.com
